Literature DB >> 19479829

Ligands for retinoic acid receptors are elevated in osteoarthritis and may contribute to pathologic processes in the osteoarthritic joint.

Mark R Davies1, Lyn Rosenbrier Ribeiro, Mark Downey-Jones, Maurice R C Needham, Caroline Oakley, John Wardale.   

Abstract

OBJECTIVE: Vitamin A derivatives, including all-trans-retinoic acid (ATRA), have a well-established role during skeletal development and limb formation and have been shown to have profound effects on chondrocyte phenotype. The aim of this study was to elucidate the effects of retinoids and components of the retinoid metabolic pathway on chondrocyte phenotype in the tibiofemoral joints of patients with osteoarthritis (OA), to show that the retinoids can have multiple effects relevant to the OA disease process.
METHODS: Human explant tissue and a chondrocyte-like cell line were treated with ATRA, and the responses of 4 key markers of chondrocyte phenotype were analyzed. In addition, the effects of ATRA on a number of novel genes associated with OA were assessed using a low-density microarray containing 80 disease marker genes.
RESULTS: Vitamin A metabolite levels were elevated in synovial fluid, serum, and cartilage from patients with OA. Expression profiling of a retinoic acid receptor alpha coactivator protein, P/CAF, demonstrated elevated expression in patients with OA, suggesting the potential for increased signaling via the retinoid receptors in the disease. ATRA increased the levels of matrix metalloproteinase 13 and aggrecanase activity in human cartilage explants and in a human chondrocyte cell line. Furthermore, ATRA altered the expression of a wide range of relevant genes, including the types I, II, IX, and XI collagen genes, toward a nonchondrogenic and OA-like phenotype.
CONCLUSION: These results suggest that retinoid signaling could have a central role in OA, and that components of the pathway may provide potential disease biomarkers or targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479829     DOI: 10.1002/art.24550

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis.

Authors:  Marian Seda; Maartje Geerlings; Peggy Lim; Jeshmi Jeyabalan-Srikaran; Ann-Christin Cichon; Peter J Scambler; Philip L Beales; Victor Hernandez-Hernandez; Andrew W Stoker; Dagan Jenkins
Journal:  Mol Syndromol       Date:  2018-07-21

2.  Synovial fluid β-endorphin level in avascular necrosis, rheumatoid arthritis, and osteoarthritis of the femoral head and knee. A controlled pilot study.

Authors:  Kálmán Toth; István Barna; György Nagy; Karoly Wellinger; Gyöngyi Horvath; Tamas Bender
Journal:  Clin Rheumatol       Date:  2010-09-21       Impact factor: 2.980

Review 3.  Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders.

Authors:  Rita Dreier
Journal:  Arthritis Res Ther       Date:  2010-09-16       Impact factor: 5.156

4.  Metabolic enrichment of omega-3 polyunsaturated fatty acids does not reduce the onset of idiopathic knee osteoarthritis in mice.

Authors:  A Cai; E Hutchison; J Hudson; Y Kawashima; N Komori; A Singh; R S Brush; R E Anderson; W E Sonntag; H Matsumoto; T M Griffin
Journal:  Osteoarthritis Cartilage       Date:  2014-07-04       Impact factor: 6.576

5.  The Fox and the Rabbits-Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's Disease.

Authors:  C J Carter
Journal:  ISRN Neurol       Date:  2011-07-12

6.  Functional Characterization of the Osteoarthritis Genetic Risk Residing at ALDH1A2 Identifies rs12915901 as a Key Target Variant.

Authors:  Colin Shepherd; Dongxing Zhu; Andrew J Skelton; Jennifer Combe; Harrison Threadgold; Linyi Zhu; Tonia L Vincent; Paul Stuart; Louise N Reynard; John Loughlin
Journal:  Arthritis Rheumatol       Date:  2018-08-23       Impact factor: 10.995

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.